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Background: Tumors of the head and neck present aggressive pathological behavior in patients due to high
expression of CDK/CCND1 proteins. P276-00, a novel CDK inhibitor currently being tested in clinic, inhibits growth
of several cancers in vitro and in vivo. The pre clinical activity of P276-00 in head and neck cancer and its potential
mechanisms of action at molecular level are the focus of the current studies.
Method: We have investigated the anti-cancer activity of P276-00 in head and neck tumors in vitro and in vivo.
Candidate gene expression profiling and cell based proteomic approaches were taken to understand the pathways
affected by P276-00 treatment.
Results: It was observed that P276-00 is cytotoxic across various HNSCC cell lines with an IC50 ranging from
1.0-1.5 μmoles/L and culminated in significant cell-cycle arrest in G1/S phase followed by apoptosis. P276-00
treatment suppressed cell proliferation through inhibition of CCND1 expression, reduced phosphorylation of
retinoblastoma protein and abrogative transcription of E2F1 gene targets. Further, we observed that apoptosis
was mediated through P53 activation leading to higher BAX/BCL-2 ratio and cleaved caspase-3 levels. It was
also seen that P276-00 treatment reduced expression of tumor micro-environment proteins such as IL-6,
secreted EGFR and HSPA8. Finally, P276-00 treatment resulted in significant tumor growth inhibition in
xenograft tumor models via lowered proliferative activity of E2F1 and aggravated P53 mediated apoptosis.
Conclusion: In summary, we have observed that P276-00 inhibits cyclin-D/CDK4/P16/pRB/E2F axis and induces
apoptosis by increased P53 phosphorylation in HNSCC cells. These results suggest a novel indication for P276-00 in
head and neck cancer with a potential role for IL-6 and HSPA8 as candidate serum biomarkers.
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Head and neck squamous cell carcinoma (HNSCC) is
the 8th most common cause of morbidity and mortality
due to cancer worldwide. Head and neck cancer refers
to carcinoma arising in the mucosal surfaces of the oral
cavity, oropharynx, larynx and hypopharynx of which
90% are HNSCC [1]. Current treatment options for* Correspondence: prabha.mishra@piramal.com
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reproduction in any medium, provided the orHNSCC include surgery, γ-irradiation, and chemother-
apy depending on the site, size and the stage of lesions.
Aberrant expression of P14, P16, P53, CCND1, RAS,
EGFR, and MYC is known to initiate tumorigenesis and
contribute towards development of HNSCCs [2]. It has
also been observed that tumor cells have deregulated
CDK or CCND1 activity or combination of both [3].
Abnormalities in the expression of a cell cycle regulatory
protein such as CCND1 due to genomic inversions,
translocation and gene amplification have been identified
as a cause for poor prognosis and drug resistance in
HNSCC. Amplification of CCND1 has been observed in
58% of cases with over expression of protein seen in 68%Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cycle progression by promoting G1/S cell cycle transi-
tion. CCND1 binds cyclin-dependent kinase 4 or 6
(CDK4/6) to form an active kinase that induces phos-
phorylation of retinoblastoma protein (RB) resulting in
release of E2F transcription factors and thereby promot-
ing transcription of genes required for cell cycle progres-
sion [6-8]. Further, inactivation of the P53 pathway is a
salient feature of molecular mechanism of HNSCC pro-
gression [9]. P53 mutations are associated with drug re-
sistance and treatment failure and determine the overall
survival of HNSCC patients [10,11]. Tumor microenvir-
onment plays a critical role in initiation and progression
of tumor and includes the extracellular matrix proteins,
cytokines, proteases and hormones [12]. IL-6, EGFR and
HSPA8 act as survival factors for neoplasm and in-
creased circulating levels of these proteins have been
observed in various types of cancer patients [12-14].
Therapeutic agents such as Erbitux (EGFR inhibitor),
Bevacizumab (VEGF inhibitor) and Erlotinib (EGFR in-
hibitor) that target cellular signaling pathways have been
developed as promising candidates to treat HNSCC [12].
At the same time, small molecules which are acting as
competitors of ATP binding with CDK are of particular
relevance in designing therapy for HNSCC.
P276-00 is a flavone with cyclin-dependent kinase in-
hibitor activity and arrests the cells in G1/S phase transi-
tion [15,16]. Kinase assay profiling studies have shown
that P276-00 selectively inhibits CDK4-CCND1 complex
as compared to CDK2-CCNE1 with a 40-fold specificity.
P276-00 is also observed to inhibit CDK9-CCNT1 medi-
ated RNA polymerase II-dependent transcription [17].
In the current study, we have investigated the activity of
P276-00 in HNSCC and explored the potential mechan-
ism of action of anti-cancer activity in multiple HNSCC
cancer cells using in vitro and in vivo models.Methods
Antibodies
Following primary antibodies were used for various ana-
lyses: CCND1, CCNE1, Phospho-RBSer780 (pRB) and E2F1
(Santa Cruz biotechnology); PCNA (Chemicon); KI67(BD
Pharmigen); cleaved-Caspase-3, phospho-P53Ser392 and
P16 (Epitomics); β-Actin antibody (Sigma).Cell lines and culture conditions
Human squamous cell carcinoma cell lines- FaDu, Detroit-
562 and SCC-25 were obtained from the American Type
Culture Collection (Manassas, VA). FaDu and Detroit-562
cells were grown in EMEM medium and SCC-25 cells
were grown in 1:1 mixture of DMEM and Ham’s F12
medium. Both the mediums were supplemented with 10%
FBS (Hyclone) and 100 U/ml penicillin (Sigma).Tumor xenograft model
All animal experiments were handled in accordance with
the guidelines of “Committee for the Purpose of Control
and Supervision of Experiments on Animals” which was
accredited by the Institutional Animal Ethics Committee
of Piramal Healthcare. FaDu cells were harvested and
re-suspended in saline at 10 million cells/0.2 mL volume
and injected to severe combined immunodeficient
(SCID) mice on right flank. Animals were randomized
when tumor size attained a diameter of ~5 mm into
control and treatment group. Treatment group received
50 mg/kg P276-00 solution in water by intraperitoneal
route for 18 days. Tumor diameters were measured
every alternate day and tumor growth inhibition (GI)
was calculated as previously reported [15,16].
Cell viability assay
The cytotoxicity of P276-00 was determined using the
cell counting kit-8 (CCK8) as per the manufacturer’s
instructions (Dojindo, Gaithersburg, MD, USA). The
change in color due to assay was measured at 450 nM
using a Tecan sapphire multi-fluorescence microplate
absorbance reader (Tecan, Germany).
Cell cycle analysis
Treated and untreated control cells were fixed in 70%
ethanol and stained with Propidium iodide (50 mg/ml)
and RNase A (1 mg/ml). DNA content was measured by
flow cytometer (FACS Calibur Becton Dickinson, San
Jose, CA). Cells with DNA content between 2 N and 4 N
were designated as being in G1, S, and G2-M phases of
the cell cycle. Cells exhibiting <2 N DNA content were
designated as sub-G0 cells. The number of cells in each
cell cycle compartment was expressed as a percentage of
the total number of cells.
mRNA expression assay
Extraction of total RNA was carried out using
chloroform-ethanol precipitation method. Cells/tissues
were lysed using Trizol Reagent (Invitrogen Corporation,
Carlsbad, USA). The RNA was purified using RNeasy
Mini kit (Qiagen GmbH, Hilden, Germany). For cDNA
conversion, 2 μg of total RNA was reverse transcribed to
cDNA using 200 units of Superscript III (Invitrogen
Corporation, Carlsbad, CA, USA) as per manufacturer’s
protocol. Further real-time PCR was performed in 96-well
plates using Realplex™ Mastercycler System (Eppendorf,
Germany) and the fluorescent SYBR green dye
(Quantifast™ SYBR Green PCR Kit., Qiagen GmbH,
Hilden, Germany). Data were analyzed using the Realplex™
software (version 1.5). The relative expression of genes
was calculated with the relative Ct method [18] using
GAPDH as housekeeping gene for normalization of data.
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FaDu cells were lysed with cell lysis buffer (cell signaling),
resolved on a 10% SDS-PAGE gels and transferred to
nitrocellulose membrane (Sigma-Aldrich, MO, USA).
Membrane was blocked with 5% non fat milk (Santa Cruz
Biotechnology, city, CA, USA) and treated with the
primary antibody overnight at 4°C followed by HRP conju-
gated secondary antibody. After incubation, bound anti-
bodies were detected with enhanced chemifluorescence
(ECF) substrate (Sigma-Aldrich, MO, USA) and analyzed
by Kodak Image station 4000MM (Kodak, Roches, CA).
Cell based automated fluorescence imaging
FaDu cells were grown in 96-well plates and treated with
different concentrations of P276-00 for 24 hours. Treated/
untreated cells were fixed with 3.7% formaldehyde (Merck
Biosciences, Darmstadt, Germany) for 20 min. and perme-
abilized using chilled permeabilization buffer (0.15%
Triton X-100; Thermo Scientific, Waltham, MA) for
1.5 min. Subsequently the cells were blocked with DPBS
containing 5% FBS and 5% goat serum (Vector Laborator-
ies Inc., Burlingame, CA) for 1 hour at room temperature.
Thereafter cells were incubated with primary antibody at
4°C overnight. This was followed by staining with
DyLight™ 549-conjugated goat antibody (Thermo Scien-
tific; Waltham, MA) and nuclear staining with Hoechst
33342 (AnaSpec Inc; Fermont, CA). The plates were
scanned to acquire images on the ArrayScan® HCS reader
(Thermo Scientific.). All the data points were analyzed
using compartmental analysis bio-algorithm (Cellomics
Inc. Pittsburgh PA). The results were expressed as per-
centage (%) deregulation as compared to control (vehicle)
cells for each protein. The 50% effective concentrations
(EC50) were calculated using nonlinear regression method
with GraphPad software (Prism 5).
Elisa
Supernatants were collected from treated and untreated
cells and assayed for HSPA8 and IL-6 by ELISA (Enzyme-
Linked Immunosorbent Assay) using HSPA8 ELISA kit
(USCN Life Sciences Inc, Wuhan, China) and IL-6 ELISA
kit (OptiEIA ELISA sets; BD Biosciences) as per the man-
ufacturer’s protocol. The 50% inhibitory concentration
(IC50) values were calculated by nonlinear regression
method using GraphPad software (Prism5).
Immunohistochemical analysis of tumor xenografts
The formalin fixed paraffin embedded sections of xeno-
graft tumor tissue from control and treated groups were
stained by immunohistochemistry for specific proteins.
The slides were deparaffinized followed by antigen re-
trieval by incubating the slides in citrate based antigen
unmasking solution (pH 6.0) (Vector Labs, CA, USA)
for 30 minutes. Slides were then blocked for two hourswith 1X blocking buffer (containing 2% FBS, 2% FCS,
5% goat serum, 5% donkey serum, 1%BSA and 0.1%
triton-x) followed by incubation with primary antibody
overnight at 4°C. Slides were incubated with secondary
antibody conjugated with DyLight 549 fluorescent dye
for 60 minutes at 37°C and mounted with Vectastain®
Elite ABC reagent. All tumor tissues without primary
antibody were used as negative control throughout the
study. Images were captured with Nikon E600 micro-
scope equipped with a DXM1200F digital camera
(Nikon USA). Pixel intensities were measured using
ImageJ software (http://rsb.info.nih.gov/ij/).
Results
In vitro activity of P276-00 on HNSCC cells
Anti-cancer properties of P276-00 were tested across
multiple HNSCC cell lines (FaDu, Detroits-562, SCC-25)
by measuring dehydrogenase based tetrazolium salt re-
duction produced by viable cells (Figure 1a). The results
showed significant inhibition of cell viability for all three
cell lines with IC50 value ranging from 0.8 to 1.7 μM de-
pending on specific cell lines.
P276-00 caused G1 arrest in FaDu cells
To determine the effect of P276-00 on specific cell cycle
stages, cells exposed to two different concentrations of the
drug were assayed for their cell cycle status at different
time points (Figure 1b). It was observed that P276-00
induced cell arrest at G1 phase within 12 hours of drug
exposure. The effect peaked after 24 hours lasting up to
48 hours. P276-00 significantly reduced cells from the S
phase in a dose-dependent manner. Our data also showed
a moderate effect of P276-00 on G2/M phase of the cell
cycle. Moreover, at 3 μM, more than 50% of cells appeared
in sub-G0 phase after 24 hours of treatment which in-
creased up to ~85% by 72 hours. These results suggest
drug induced cell cycle blockade in G1 phase followed by
apoptosis, as indicated by the appearance of cells with
sub-G0 DNA content.
P276-00 targeted CCND1/pRB mediated E2F1 pathway
causing G1 arrest in FaDu cells
To establish the anti-proliferative properties of P276-00
via G1 arrest, we have investigated the status of
CCND1/pRB mediated E2F1 signaling components in
FaDu cells treated with or without P276-00 (Figure 2a).
Treatment of FaDu cells with P276-00 showed a reduc-
tion in pRB and CCND1 protein levels as early as 6 hours
and was maintained upto 24 hours. P276-00 also re-
duced E2F1 and CCNE1 protein expression by 24 hours
(Figure 2a).
The inhibitory effect of P276-00 on E2F1 was further
confirmed by measuring E2F1 target gene expression.
P276-00 significantly inhibited twelve E2F1 targeted cell
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Figure 1 In vitro efficacy of P276-00 caused by G1 arrest in HNSCC cells (a) Anti-proliferative effect of P276-00 on HNSCC cells using
CCK-8 assay. Cells (Detroite-562, filled circles; SCC25, filled triangles, and FaDu, filled boxes) were treated to 5 different concentrations of P276-00
(range: 0.1-10 μM) and measured after 48 hours. Here data is expressed in % cytotoxicity mean ± S.E.M. (n = 3). The IC50 of each cell line was
calculated. (b) Flow cytometric analysis of asynchronous population of FaDu cells exposed to either P276-00 (1 and 3 μM) or DMSO for different
time points (12, 16, 24, 48 and 72 hours). Histograms of cellular DNA content obtained by flow cytometry have been represented. The (%) DNA
content for each phase of the cell cycle is indicated, which was determined by ModFit analysis.
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p < 0.05) as compared to untreated cells. Amongst these
genes, CCND1, CCNE1, PCNA, KI67, cMYC, RRM2
and E2F1 expressions were consistently inhibited in a
dose- and time-dependent manner upto 12 hours (only
cMYC show a strong repression as early as in 3 hours)
(Figure 2b, 2c). We observed a moderate inhibition of
transcripts for CCNB1, PLK1 and BUB1 at all time
points. In addition, transcript levels of negative cell cycle
regulators including P16 and P14 were elevated in
response to P276-00 exposure in a time-dependent
manner. (Figure 2b, 2c)
Automated fluorescence imaging approach was used
to measure the proteins that indicated molecularchanges in response to P276-00 in FaDu cell lines. There
was significant inhibition in expression of cell cycle pro-
teins including CCND1, CCNE1, KI67, E2F1 and pRB.
However, we found increased levels of P16 protein in re-
sponse to P276-00 (Figure 2d, 2e). We determined the
effective concentration (EC50) of P276-00 for specific
target proteins (Figure 2d). Put together, these results
suggest the inhibition order from low to high EC50 value
as CCND1 (0.4 μM), KI67 (0.6 μM), CCNE1 (0.7 μM),
pRB (0.9 μM) and E2F1 (1.1 μM). Furthermore, the
slopes of dose–response plots (‘Hill’ slopes) were deter-
mined for the inhibition of all the proteins across 8 vari-
ous concentrations. Two major observations emerged:
The Hill slopes remains ~1 for CCNE1, KI67 and pRB
Phos-RB
Cyclin D1
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Figure 2 (See legend on next page.)
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Figure 2 P276-00 targeting CCND1/pRB mediated E2F1 pathway and causing G1 arrest in FaDu cells. (a) Western blot analysis of CCND1,
pRb, CCNE1 and E2F1 in FaDU cells treated with 1 and 3 μM P276-00 for 3, 6, 12 and 24 hours.(b-c) RTQPCR based transcript profiling of various
downstream targets of E2F1 pathway. Data is represented on log2 scale as mean ± S.E.M. (n=3-5). (b) Dose response - FaDu cells were exposed
to 5 different concentrations of P276-00 (range: 0.1-10 μM) for 12 hours in FaDu cells. (c) Time response- cells were exposed to 4 different time
points (3, 6, 12 and 24 hours) with 1 μΜ of P276-00 (d-e) Automated fluorescence imaging based dose dependent protein profiling of CCND1/
pRB mediated E2F1 pathway and its downstream targets. FaDu cells (1–2 × 104 cells/ml) were treated with 8 different concentrations of P276-00
(range 0.03 to 10 μM) for 24 hours and observed using ArrayScan HCS reader after staining with respective antibody (d) Quantification of the
automated fluorescence imaging data has been represented in sigmoidal dose response curve where compound concentration. is represented in
log2 scale. One thousand cells were counted for each replicate well and the results were presented as an average ± S.E.M. (n = 3). EC50 values
have been generated for all the 5 proteins. (e) Panel of representative images.
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Figure 3 Cytotoxic nature of P276-00 is due to phosphorylation of P53 in FaDu cells. (a) Western blot analysis of phosphorylated-P53 in
FaDu cells treated with 1 and 3 μM P276-00 for the 24 hours. (b) Dose dependent relative mRNA expression of downstream target of P53 after
24 hours of treatment. Data in histograms represented on log2 scale as mean ± S.E.M. (n = 3). (c-d) Dose dependent treatment of P276-00
(8 different concentrations -range 0.03 to 10 μM) for 24 hours has shown induction of P53 phosphorylation at Ser392 and cleavage of CASP3 in
FaDu cells detected by Automated fluorescence imaging (HCS reader) (c) Graphical representation of the data (d) Representative images.
Mishra et al. Journal of Translational Medicine 2013, 11:42 Page 6 of 11
http://www.translational-medicine.com/content/11/1/42
Mishra et al. Journal of Translational Medicine 2013, 11:42 Page 7 of 11
http://www.translational-medicine.com/content/11/1/42with 8 different concentrations of the P276-00 suggesting
that the proteins are inhibited in dose dependent manner.
The steep Hill slopes with >3.4 value for CCND1 and
E2F1 indicate an on-off response with treatment.P276-00 induced apoptosis through phosphorylation of
P53 in FaDu cells
The extent of apoptosis is maintained by a well regulated
balance between pro- and anti-apoptotic factors. In this
regard, we demonstrated that P276-00 induced the ex-
pression of proapoptotic gene BAX at 12 hours of treat-
ment and attenuated expression of anti-apoptotic genes
BCL2 and MCL1 (Figure 3b). Cleaved CASP3, critical
for induction of apoptosis, was also elevated in response
to P276-00 in a dose-dependent manner (Figure 3c, 3d).
To further probe the apoptotic mechanism of P276-00,
we observed that P53 phosphorylation was significantly el-
evated in vitro in response to P276-00 (Figure 3a, 3c, 3d).
This observation is consistent with an increase in BAX
and BCL2 genes (Figure 3b), since the latter are P53 target


























































Figure 4 P276-00 inhibit growth signaling proteins and cytokine in F
in FaDu cells. The relative expression level of these genes was measured in
(b) dose response. (c-d) P276-00 potently suppresses in vitro production of
± S.E.M. (n=3-5) * indicates p-val < = 0.05 as compared to DMSO pre-treateP276-00 inhibited growth signaling proteins and
cytokines in FaDu cells
We examined growth and immune signalling proteins
such as EGFR, HSPA8 and cytokines IL-6 that are
involved in the survival of tumor. There was a marked
inhibition of HSPA8 and IL-6 genes at mRNA level in
dose- and time-dependent manner (Figure 4a, 4b). In
congruence with the gene expression, P276-00 signifi-
cantly inhibited IL-6 and HSPA8 protein levels measured
by ELISA with IC50 at 1.4 μM and 1.2 μM respectively
(Figure 4c, 4d). EGFR gene expression was significantly
reduced by 1 μM P276-00 in a time-dependent manner
with maximal inhibition at 24 h (Figure 4b). Additional
file 1: Figure S1 showed a marked dose-dependent inhib-
ition of EGFR gene expression at 24 h with a not so
robust dose–response effect at 12 h (Figure 4a).Effects of P276-00 in vivo on FaDu xenograft model
Given the significant anti-proliferative and pro-apoptotic
effects of P276-00 in HNSCC in vitro, we investigated





















































aDu cells. (a-b) P276-00 inhibits mRNA level of IL-6, EGFR and HSPA8
comparison with control sample (a) Time dependent response
IL-6 and HSPA8 in FaDu cells. (c) IL-6 (d) HSPA8. All values are average
d control cells.
Figure 5 Effects of P276-00 on FaDu xenograft. Average tumor growth of HNSCC (FaDu) xenograft over a period of 18 day after
randomization. Group treated with P276-00 (shaded square), control group (open square) (n = 6).
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in vivo activity with a 48% tumor growth inhibition
(TGI) on day 18 (Figure 5). Consistent with the in vitro
evidence, P276-00 inhibited cell cycle gene expression in
the tumor tissue including CCND1, CCNE1, cMYC,
KI67 and PCNA (>1.8 fold inhibition or fold change in
gene expression compared to control group Figure 6a).
Immunohistochemical analysis of tumor tissue for mo-
lecular targets of cell cycle such as CCND1, CCNE1,
pRB and PCNA demonstrated a significant decrease in
expression level accompanied by a moderate decrease in
KI67 in response to P276-00 treatment (Figure 6b, 6c).
Similar to in vitro studies, FaDu xenograft tumors
showed increased levels of phosphorylated P53 in re-
sponse to P276-00 administration (Figure 6b, 6c).
Discussion
P276-00, a novel CDK inhibitor, is currently under clin-
ical investigation for HNSCC (http://clinicaltrials.gov/
show/NCT00824343). In the present study, we have
demonstrated anti-cancer properties of P276-00 against
HNSCC using in vitro and in vivo tumor models. We
observed significant inhibition of E2F1 and its targets via
reduced RB phosphorylation by P276-00. We also dem-
onstrated that P276-00 promoted apoptosis by phos-
phorylation of P53 resulting in increased BAX/BCL2
ratio and elevated levels of cleaved caspase-3. Further-
more, P276-00 inhibited expression of soluble proteins
such as IL-6, EGFR and HSPA8 that promote tumor
microenvironment.
The anti-cancer properties of flavones such as flavopiridol
through CDK inhibition have been established in head
and neck cancer [19]. P276-00, a flavone with a specificCDK1/4/9 inhibition activity, has been studied for anti-
cancer effects in several other cancers but not HNSCC
[15,16]. In the current study, we demonstrated the anti-
cancer properties of P276-00 in HNSCC. Cell lines over
expressing CCND1 viz., FaDu, Detroits-562 and SCC-
25 were very sensitive to P276-00 as observed in the cyto-
toxicity assay, which is similar to previously reported
evidence in other cell lines [15,16]. As FaDu cells have
highest CCND1 expression and accordingly showed
highest in vitro sensitivity to P276-00, we employed these
cells for subsequent investigations in vitro and in vivo.
We observed that P276-00 resulted in 48% tumor
growth inhibition (TGI) by day 18 post drug administra-
tion with minimal toxicity to animals as observed by the
animal body weight loss (less than 10% of total body
weight loss -data not shown) in the FaDu xenograft
model. This TGI value is comparable to the reported
data for anti-tumor activity (40% optimal TGI) [20].
Thus our in vivo study with FaDu xenograft model
establishes the therapeutic validity of P276-00.
CDK inhibitors interfere with the cell cycle progres-
sion through inhibition of cell proliferation and induc-
tion of apoptosis. We have evaluated the status of
P276–00 treated FaDu cells by flow cytometry and ob-
served that P276-00 blocks cell cycle progression by G1
arrest. Our findings are in accordance with a prior re-
port by Carlson and colleagues, who demonstrated that
flavopiridol causes cell cytotoxicity by G1-S phase arrest
in MDA-MB-468 breast carcinoma cells [21]. RB protein,
a tumor suppressor that blocks E2F transcription factor,
regulates transcription of E2F-responsive genes involved
in cell cycle progression from G1 to S phase. It is well
established that CDK4/CCND1 complex phosphorylates



















































Figure 6 Effects of P276-00 on CCND1/pRB mediated E2F1 pathway in FaDu xenograft model. a) RTQPCR based mRNA profiling of E2F1
downstream targets using tumor from HNSCC (FaDu) xenograft model. Data is represented at log2 scale mean ± S.E.M. (n = 3–4). (b)
Representative images from immunohistochemical analysis of various proteins in FaDu xenograft tumors- P276-00 treated mice (right) or vehicle
(left), (c) graphical representation of immunohistological score.
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genes such as cMYC, CCNE1, PCNA, KI67, RRM2 and
E2F1 [22-26] which are crucial for the entry of cells into
the S phase. On the contrary, P16 inhibits phosphoryl-
ation of RB protein and attenuates E2F1 activity. Loss of
P16 expression has been observed in 55% of HNSCC tu-
mors [4]. We observed a significant inhibition of CCND1
expression and RB phosphorylation followed by reduced
transcription of E2F1 targeted genes in presence of P276-
00 under both in vitro and in vivo conditions. The on-off
dose-responses for CCND1 and E2F1 have important clin-
ical implications suggesting that lower concentrations of
P276-00 can be clinically used without noticeable loss inefficacy. These observations suggest that P276-00 medi-
ates its anti-proliferative activity via inhibition of CCND1/
pRB/E2F1 pathway leading to G1-S phase arrest. On the
other hand, G2/M check point markers CCNB1, PLK1
and BUB1 [25,27] showed marginal inhibition by P276-00,
which further compliments the moderate arrest of cells in
G2/M phase in FACS analysis. Human ARF/INK4a locus
encodes two cell cycle inhibitors, P16INK4a (P16) and
P14ARF (P14), which are directly modulated by E2F1
[28,29]. P276-00 induced the expression of P16 and P14 in
a time-dependent manner at lower dose levels. Low levels
of P16 and P14 transcript observed with the higher con-
centration of P276-00 could be due to overall E2F1
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poral relationship among abrogated levels of phosphory-
lated RB and E2F1 targets explains inhibition of G1 phase
of the cell cycle via CCND1/pRB/E2F1 pathway.
Prolonged cell cycle arrest causes apoptosis [30]. FaDu
cells are known to express mutant P53 with a point
mutation on codon 248 [31]. Despite this point muta-
tion, phosphorylation of P53 at Ser392 results in transac-
tivation of P53 and oncogenic function of P53 mutant
[32]. Activated (phosphorylated) P53 trans-represses
anti-apoptotic BCL-2 [33,34] and over expresses pro-
apoptotic BAX [33], which triggers the caspase cascade.
Consistently, P276-00 treatment in FaDu cells showed
increased P53 phosphorylation at Ser392 and cleaved
CASP-3 expression along with reduced BCL2 to BAX
ratio, which was associated with enhanced apoptosis
(measured by FACS). The decrease in proapoptotic BAX
mRNA expression at higher concentrations of P276-00
could be due to overall CDK9/CyclinT1-mediated re-
pression of basal transcriptional machinery by P276-00
[17]. However, this needs additional validation.
Growth signaling proteins and cytokines, that promote
cell growth, inflammation, and angiogenesis, play an im-
portant role in tumor microenvironment enhancing
tumor proliferation, invasion, and metastasis [35]. Mo-
lecular pathogenesis of HNSCC is also driven by similar
alterations in growth and immune signalling [12,36].
HNSCC tumors get nourished due to its microenviron-
ment and are well supplied with soluble epidermal
growth factor receptor (EGFR) and cytokine (IL-6),
which play a critical role in tumor aggressiveness and
their response to various therapies [12,36]. Higher levels
of IL-6 and EGFR in HNSCC cancer patients’ serum are
found to be associated with a higher second primary
cancer (SPC) specific mortality and hence established as
serum biomarkers for HNSCC [14]. Dose-dependent
inhibition of EGFR and IL-6 by P276-00 supports its
sensitivity against growth promotion of HNSCC. Add-
itionally, HSPA8 is a member of the heat-shock protein
70 families and known to promote cancer cell growth
[13]. HSPA8 is important for stability of CCND1 mRNA
and also helps to form a complex with CDK4 [37]. Inter-
estingly, we have observed significant inhibition of
HSPA8 by P276-00 at mRNA and protein levels in dose-
dependent manner. Based on these observations, we
propose that the secretary levels of IL-6 and HSPA8
could be the potential efficacy biomarker for P276-00
treatment in the clinic.
Conclusions
We conclude that P276-00 has potent anti-proliferative
and anti-tumor effects in HNSCC in vitro and in vivo.
The findings from our study provide mechanistic in-
sights into the anti-cancer activity of P276-00 and itseffect on CCND1/CDK4/P16/pRB/E2F signaling cascade
in FaDu cells. Being the key mediators of cancer survival,
pharmacological inhibition of E2F1 targets is an attract-
ive option for therapeutic intervention against cancer.
Therefore, P276-00 can serve as a promising candidate
in HNSCC therapy, particularly for those lesions that
over expresses CCND1 and are insensitive to conven-
tional therapy.
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